Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 552

1.

What Is the Significance of Variant Histology in Urothelial Carcinoma?

Lobo N, Shariat SF, Guo CC, Fernandez MA, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA 3rd, Roupret M, Kamat AM.

Eur Urol Focus. 2019 Sep 14. pii: S2405-4569(19)30278-0. doi: 10.1016/j.euf.2019.09.003. [Epub ahead of print] Review.

PMID:
31530497
2.

Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.

Moschini M, Shariat SF, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupret M, Boorjian SA, Catto JW, Sanchez-Salas R.

Eur Urol. 2019 Sep 7. pii: S0302-2838(19)30670-0. doi: 10.1016/j.eururo.2019.08.021. [Epub ahead of print]

PMID:
31506227
3.

Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.

Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB.

Eur Urol Oncol. 2019 Sep;2(5):497-504. doi: 10.1016/j.euo.2018.07.009. Epub 2018 Aug 17.

PMID:
31411998
4.

Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?

Burger M, Kamat AM, McConkey D.

Eur Urol Oncol. 2019 Aug 6. pii: S2588-9311(19)30093-8. doi: 10.1016/j.euo.2019.06.012. [Epub ahead of print]

5.

Spectrum of Movement Disorders in Patients With Neuroinvasive West Nile Virus Infection.

Lenka A, Kamat A, Mittal SO.

Mov Disord Clin Pract. 2019 Jul 16;6(6):426-433. doi: 10.1002/mdc3.12806. eCollection 2019 Jul. Review.

PMID:
31392241
6.

Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series.

Seiler R, Black PC, Williams SB, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ.

Urol Oncol. 2019 Jul 31. pii: S1078-1439(19)30254-6. doi: 10.1016/j.urolonc.2019.06.025. [Epub ahead of print] Review. No abstract available.

PMID:
31377169
7.

Reply to "Cerebrospinal fluid protein and shunt obstruction in tuberculous meningitis".

Kamat AS, Gretschel A, Vlok AJ, Solomons R.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):767-768. doi: 10.5588/ijtld.18.0789. No abstract available.

PMID:
31315715
8.

How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?

Kamat AM, Gontero P, Palou J.

Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30094-X. doi: 10.1016/j.euo.2019.06.013. [Epub ahead of print]

9.

Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.

Pignot G, Loriot Y, Kamat AM, Shariat SF, Plimack ER.

Eur Urol Oncol. 2019 Jul;2(4):355-364. doi: 10.1016/j.euo.2019.01.002. Epub 2019 Jan 31. Review.

PMID:
31277773
10.

Bioinspired Cilia Sensors with Graphene Sensing Elements Fabricated Using 3D Printing and Casting.

Kamat AM, Pei Y, Kottapalli AGP.

Nanomaterials (Basel). 2019 Jun 30;9(7). pii: E954. doi: 10.3390/nano9070954.

11.

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM.

Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.

PMID:
31200843
12.

Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB.

JAMA Surg. 2019 Jun 5:e191629. doi: 10.1001/jamasurg.2019.1629. [Epub ahead of print]

PMID:
31166593
13.

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC.

Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Review.

PMID:
31102625
14.

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM.

Eur Urol Oncol. 2018 Aug;1(3):190-198. doi: 10.1016/j.euo.2018.05.002. Epub 2018 May 30. Review.

PMID:
31102620
15.

Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers.

Briganti A, Albiges L, Giannarini G, Kamat AM, Nguyen PL.

Eur Urol Oncol. 2018 May;1(1):1-2. doi: 10.1016/j.euo.2018.04.002. Epub 2018 May 15. No abstract available.

PMID:
31100222
16.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
17.

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer.

Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE 3rd, Huang H, Dadhania V, Gao J, Dinney C, Weinstein JN, Baggerly K, McConkey D, Czerniak B.

Cell Rep. 2019 May 7;27(6):1781-1793.e4. doi: 10.1016/j.celrep.2019.04.048.

18.

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts.

Maulhardt HA, Hylle L, Frost MV, Tornio A, Dafoe S, Drummond L, Quinn DI, Kamat AM, diZerega GS.

Cancers (Basel). 2019 Apr 24;11(4). pii: E577. doi: 10.3390/cancers11040577.

19.

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.

Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. Review.

PMID:
31019310
20.

Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer.

Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL.

Eur Urol Oncol. 2019 Mar;2(2):119-125. doi: 10.1016/j.euo.2018.07.006. Epub 2018 Aug 14.

PMID:
31017086
21.

Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.

Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM.

Future Oncol. 2019 Apr;15(12):1323-1334. doi: 10.2217/fon-2018-0654. Epub 2019 Apr 3.

PMID:
30942088
22.

The role of metastatic burden in cytoreductive/consolidative radical cystectomy.

Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N.

World J Urol. 2019 Mar 12. doi: 10.1007/s00345-019-02693-y. [Epub ahead of print]

PMID:
30864005
23.

New horizons in bladder cancer research.

Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Mar 7. pii: S1078-1439(18)30508-8. doi: 10.1016/j.urolonc.2018.12.014. [Epub ahead of print] Review.

PMID:
30852032
24.

Clinical and Genomic Considerations for Variant Histology in Bladder Cancer.

Matulay JT, Narayan VM, Kamat AM.

Curr Oncol Rep. 2019 Feb 26;21(3):23. doi: 10.1007/s11912-019-0772-8. Review.

PMID:
30806832
25.

The impact of squamous histology on survival in patients with muscle-invasive bladder cancer.

Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB.

Urol Oncol. 2019 Jun;37(6):353.e17-353.e24. doi: 10.1016/j.urolonc.2019.01.020. Epub 2019 Jan 28.

PMID:
30704959
26.

Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Jan 22. pii: S1078-1439(19)30003-1. doi: 10.1016/j.urolonc.2019.01.003. [Epub ahead of print] Review.

PMID:
30683454
27.

Exposure to cuticular bacteria can alter host behavior in a funnel-weaving spider.

Parks OB, Kothamasu KS, Ziemba MJ, Benner M, Cristinziano M, Kantz S, Leger D, Li J, Patel D, Rabuse W, Sutton S, Wilson A, Baireddy P, Kamat AA, Callas MJ, Borges MJ, Scalia MN, Klenk E, Scherer G, Martinez MM, Grubb SR, Kaufmann N, Pruitt JN, Keiser CN.

Curr Zool. 2018 Dec;64(6):721-726. doi: 10.1093/cz/zox064. Epub 2017 Nov 16. Erratum in: Curr Zool. 2018 Jun;64(3):405.

28.

Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.

Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE.

World J Urol. 2018 Dec 7. doi: 10.1007/s00345-018-2591-1. [Epub ahead of print]

PMID:
30535583
29.

Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer-Reply.

Williams SB, Kamat AM, Mehta HB.

JAMA Surg. 2019 Feb 1;154(2):186. doi: 10.1001/jamasurg.2018.4372. No abstract available.

PMID:
30476959
30.

Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model.

Ray-Zack MD, Shan Y, Mehta HB, Yu X, Kamat AM, Williams SB.

Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30431-9. doi: 10.1016/j.urolonc.2018.10.024. [Epub ahead of print] Review.

PMID:
30446462
31.

Erratum: Exposure to cuticular bacteria can alter host behavior in a funnel-weaving spider.

Parks OB, Kothamasu KS, Ziemba MJ, Benner M, Cristinziano M, Kantz S, Leger D, Li J, Patel D, Rabuse W, Sutton S, Wilson A, Baireddy P, Kamat AA, Callas MJ, Borges MJ, Scalia MN, Klenk E, Scherer G, Martinez MM, Grubb SR, Kaufmann N, Pruitt JN, Keiser CN.

Curr Zool. 2018 Jun;64(3):405. doi: 10.1093/cz/zoy013. Epub 2018 Feb 6.

32.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

33.

Current Use and Promise of Urinary Markers for Urothelial Cancer.

Tabayoyong W, Kamat AM.

Curr Urol Rep. 2018 Oct 17;19(12):96. doi: 10.1007/s11934-018-0857-1. Review.

PMID:
30328534
34.

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.

Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM.

Eur Urol. 2019 Jan;75(1):8-10. doi: 10.1016/j.eururo.2018.09.028. Epub 2018 Oct 6.

PMID:
30301695
35.

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.

Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF.

Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26.

PMID:
30268659
36.

Evaluation of locally manufactured patient-specific custom made implants for cranial defects using a silicone mould.

Vlok AJ, Naidoo S, Kamat AS, Lamprecht D.

S Afr J Surg. 2018 Sep;56(3):38-42.

PMID:
30264941
37.

Editorial comment.

Kamat AM, Gontero P.

Curr Opin Urol. 2018 Nov;28(6):555-556. doi: 10.1097/MOU.0000000000000551. No abstract available.

PMID:
30256260
38.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB.

Eur Urol Focus. 2018 Jul;4(4):512-521. doi: 10.1016/j.euf.2018.08.019. Epub 2018 Sep 3.

PMID:
30190111
39.

New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ.

Bladder Cancer. 2018 Jul 30;4(3):339-342. doi: 10.3233/BLC-189032. No abstract available.

40.

Advances in risk stratification of bladder cancer to guide personalized medicine.

Matulay JT, Kamat AM.

F1000Res. 2018 Jul 25;7. pii: F1000 Faculty Rev-1137. doi: 10.12688/f1000research.14903.1. eCollection 2018. Review.

41.

Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer.

Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM.

World J Urol. 2019 Jan;37(1):3-13. doi: 10.1007/s00345-018-2436-y. Epub 2018 Aug 13. Review.

PMID:
30105454
42.

Esophageal perforation as a complication of the Heimlich maneuver in a pediatric patient: A case report.

Koss SL, Karle WE, Dibelius G, Kamat A, Berzofsky C.

Ear Nose Throat J. 2018 Jul;97(7):E1-E3.

PMID:
30036437
43.

Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort.

Kukreja JB, Metcalfe MJ, Qiao W, Kamat AM, Dinney CPN, Navai N.

Eur Urol Focus. 2018 Jul 19. pii: S2405-4569(18)30167-6. doi: 10.1016/j.euf.2018.07.001. [Epub ahead of print]

PMID:
30033071
44.

Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.

Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS.

Eur Urol. 2018 Nov;74(5):597-608. doi: 10.1016/j.eururo.2018.06.024. Epub 2018 Jul 13.

PMID:
30017405
45.

Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study.

Smith AB, Daneshmand S, Patel S, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Taylor J, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Lotan Y; Flexible Blue Light Study Group Collaborators.

BJU Int. 2019 Jan;123(1):35-41. doi: 10.1111/bju.14481. Epub 2018 Aug 11.

PMID:
29979488
46.

Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.

Williams SB, Shan Y, Jazzar U, Mehta HB, Baillargeon JG, Huo J, Senagore AJ, Orihuela E, Tyler DS, Swanson TA, Kamat AM.

JAMA Surg. 2018 Oct 1;153(10):881-889. doi: 10.1001/jamasurg.2018.1680.

47.

CSF protein concentration associated with ventriculoperitoneal shunt obstruction in tuberculous meningitis.

Kamat AS, Gretschel A, Vlok AJ, Solomons R.

Int J Tuberc Lung Dis. 2018 Jul 1;22(7):788-792. doi: 10.5588/ijtld.17.0008.

PMID:
29914605
48.

Salvage topical therapy for upper tract urothelial carcinoma.

Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

World J Urol. 2018 Dec;36(12):2027-2034. doi: 10.1007/s00345-018-2349-9. Epub 2018 May 26.

PMID:
29804202
49.

Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.

Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC.

Hum Pathol. 2018 Sep;79:57-65. doi: 10.1016/j.humpath.2018.05.005. Epub 2018 May 12.

50.

Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy.

Flannery K, Cao X, He J, Zhong Y, Shah AY, Kamat AM.

Clin Genitourin Cancer. 2018 Aug;16(4):e909-e917. doi: 10.1016/j.clgc.2018.03.002. Epub 2018 Mar 27.

Supplemental Content

Support Center